Technical Analysis for GWPH - GW Pharmaceuticals Plc

Grade Last Price % Change Price Change
A 218.9 0.04% 0.09
GWPH closed up 0.04 percent on Friday, April 16, 2021, on 39 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Flat
Historical GWPH trend table...

Date Alert Name Type % Chg
Gilligan's Island Sell Setup Bearish Swing Setup 3.56%
New 52 Week Closing High Bullish 3.56%
Pocket Pivot Bullish Swing Setup 3.56%
Volume Surge Other 3.56%
Calm After Storm Range Contraction 3.56%
New 52 Week High Strength 3.56%
Parabolic Rise Strength 3.56%
1,2,3 Pullback Bullish Bullish Swing Setup 49.68%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 49.68%
Calm After Storm Range Contraction 49.68%
Older End-of-Day Signals for GWPH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GW Pharmaceuticals Plc Description

GW Pharmaceuticals plc, together with its subsidiaries, engages in the research, development, and commercialization of a range of cannabinoid prescription medicines. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in treatment of cancer pain. In addition, the company has two product candidates in Phase II trials in the field of diabetes and inflammation, as well as pre-clinical research programmes evaluating the use of selected cannabinoids for the treatment of glioma, epilepsy, and psychiatric illness. It has a strategic alliance with Otsuka Pharmaceutical Co. Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Cancer Pharmaceutical Industry Clinical Development Pain Drugs Treatment Of Cancer Diabetes Medication Inflammation Cannabis Clinical Research Symptoms Epilepsy Neuropathic Pain Cannabinoid Glioma Cannabinoids Medical Cannabis Research Treatment Of Ms

Is GWPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 219.0
52 Week Low 87.07
Average Volume 873,069
200-Day Moving Average 141.99
50-Day Moving Average 215.66
20-Day Moving Average 217.37
10-Day Moving Average 218.03
Average True Range 1.24
ADX 56.26
+DI 30.59
-DI 9.19
Chandelier Exit (Long, 3 ATRs ) 215.27
Chandelier Exit (Short, 3 ATRs ) 217.84
Upper Bollinger Band 219.64
Lower Bollinger Band 215.09
Percent B (%b) 0.84
BandWidth 2.09
MACD Line 2.38
MACD Signal Line 2.99
MACD Histogram -0.6162
Fundamentals Value
Market Cap 6.83 Billion
Num Shares 31.2 Million
EPS 1.07
Price-to-Earnings (P/E) Ratio 205.54
Price-to-Sales 8.16
Price-to-Book 5.42
PEG Ratio 0.37
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 219.87
Resistance 3 (R3) 219.79 219.40 219.71
Resistance 2 (R2) 219.40 219.15 219.43 219.65
Resistance 1 (R1) 219.15 219.00 219.27 219.22 219.60
Pivot Point 218.75 218.75 218.81 218.79 218.75
Support 1 (S1) 218.50 218.51 218.63 218.58 218.20
Support 2 (S2) 218.11 218.35 218.14 218.15
Support 3 (S3) 217.86 218.11 218.09
Support 4 (S4) 217.93